The expert panel advising the Indian drug regulator has given its nod to the three-dose needle free Covid-19 vaccine from Cadila Healthcare (Zydus Cadila), claimed sources in the know. Once the Drugs Controller General of India approves the emergency use authorization (EUA), this would be the world’s first DNA-plasmid vaccine.
The Cadila Healthcare stock ended down 1.38 per cent on the BSE on Friday.
A source close to the development told Business Standard, “A regulatory approval is expected to come through anytime now. The process for that is on. The expert panel has given the green signal for the three dose regimen